TOKYO, Apr 30 (Pulse News Wire) – Eisai CO.,LTD. (4523.T) reported global sales revenue for its anti-Amyloid beta protofibril antibody drug Leqembi® (generic name: lecanemab) exceeded expectations for the fiscal year ending March 31, 2026, totaling ¥88.00 billion.
In detail, the United States contributed ¥44.60 billion, Japan accounted for ¥24.40 billion, and China generated ¥12.40 billion. Eisai disclosed these figures alongside Biogen Inc.'s (NASDAQ: BIIB) first-quarter earnings release scheduled for April 29, 2026.
Further specifics on Leqembi's performance will be revealed during Eisai’s planned earnings presentation on May 15, 2026. Regarding Leqembi, Eisai leads development and regulatory filings globally, with commercialization and promotional activities conducted jointly with Biogen under Eisai's final decision-making authority.
🟢 Confidence: High AI-translated content.